Circularization for in vitro reporting of cleavage effects by sequencing (CIRCLE-seq) is a sensitive and unbiased method for defining the genome-wide activity (on-target and off-target) of CRISPR-Cas9 nucleases by selective sequencing of nuclease-cleaved genomic DNA (gDNA). Here, we describe a detailed experimental and analytical protocol for CIRCLEseq. The principle of our method is to generate a library of circularized gDNA with minimized numbers of free ends. Highly purified gDNA circles are treated with CRISPR-Cas9 ribonucleoprotein complexes, and nuclease-linearized DNA fragments are then ligated to adapters for high-throughput sequencing. The primary advantages of CIRCLE-seq as compared with other in vitro methods for defining genome-wide genome editing activity are (i) high enrichment for sequencing nuclease-cleaved gDNA/low background, enabling sensitive detection with low sequencing depth requirements; and (ii) the fact that paired-end reads can contain complete information on individual nuclease cleavage sites, enabling use of CIRCLE-seq in species without high-quality reference genomes. The entire protocol can be completed in 2 weeks, including time for gRNA cloning, sequence verification, in vitro transcription, library preparation, and sequencing.
Introduction
Targeted genome editing is enabled by engineered nucleases such as meganucleases 1 , zinc fingers (ZFNs) 2 , transcription activator-like effector nucleases (TALENs) 3, 4 and CRISPR-Cas nucleases 4, 5 , enzymes that can introduce targeted DNA double-stranded breaks (DSBs) into the genomes of living cells. Nuclease-induced DSBs can typically undergo repair by one of the two major DNA damage repair pathways: error-prone nonhomologous end joining (NHEJ), which often results in variablelength insertion or deletion (indel) mutations, or relatively precise homology-directed repair 4, 6 . Engineered nucleases can introduce undesired off-target mutations in living cells and organisms 7, 8 , potentially leading to unintended effects in research and clinical applications. Unlike integrating viral methods for genome modification, nuclease-induced indel mutations cannot be easily detected by anchored PCR amplification of an expected sequence. Therefore, sensitive and unbiased genome-wide methods are required to fully understand the genomic locations and frequency of nuclease-induced DSB activity. Although there are many situations in which it may be helpful to recognize the genomewide activities of specific genome editing nucleases, it is particularly important in the context of clinical applications in which millions or billions of cells may be modified, and rare off-target mutations could confer an undesired proliferative advantage and increased oncogenic potential.
Development of CIRCLE-seq
Here, we present a detailed working protocol for identifying the genome-wide activity of CRISPR-Cas nucleases, called CIRCLE-seq 9 . CIRCLE-seq is an in vitro screening strategy for defining nucleaseinduced off-target DSBs in a sensitive and unbiased fashion that overcomes sensitivity limitations of cell-based methods for genome-wide off-target detection. CIRCLE-seq is based on the circularization of randomly sheared gDNA using a restriction-enzyme independent strategy followed by exonuclease treatment, thereby generating a population of covalently closed, circular double-stranded DNA molecules. Subsequently, nuclease-induced cleavage of these covalently closed DNA molecules at on-and off-target sites releases free DNA ends that serve as substrates for adapter ligation, enabling the selective sequencing of Cas9-cleaved gDNA molecules. Each pair of reads from Cas9-cleaved DNA can contain complete sequence information for a single on-target or off-target site. Because CIRCLE-seq reduces the sequencing coverage requirements for sensitive detection of CRISPR-Cas nuclease cleavage activity from human gDNA, the method can be run in any lab with access to high-throughput sequencing capability.
Comparison with other methods
There are a range of genome-wide methods that have recently been developed for detecting off-target activity of engineered nucleases 10 (Table 1) . These methods can be divided into two broad categories: cell-based and cell-free (in vitro) approaches. In general, cell-based approaches can directly discover off-target sites that are cleaved in a specific cell type; however, such methods also require the ability to culture and transfect cells of interest and are subject to potential fitness effects conferred by off-target mutations. By contrast, in vitro methods can be more highly sensitive and more scalable than cell-based methods. Both approaches ultimately require follow-up cell-based validation to confirm 10, 11 Cell-based method in which integrasedefective lentiviral vectors are integrated with a selective marker into sites of nuclease-induced DSBs. Vector integration sites are recovered by linear amplificationmediated PCR (LAM-PCR), followed by high-throughput sequencing Certain cell types may be more amenable to infection with IDLV than transfection with a double-stranded oligodeoxynucleotide (dsODN) tag
Relatively insensitive due to the integration efficiency and the requirement for positive selection to overcome this; high level of background, as IDLVs still retain some capability to randomly integrate into the cellular genome in the absence of nuclease-induced DSBs; IDLV integrations can occur some distance from the nuclease-induced break, so it may be more challenging to map sites GUIDEseq 10, 12, 13 Based on efficient integration of dsODN tags at DSBs by NHEJ in living cells, followed by tag-specific amplification and high-throughput sequencing High efficiency of dsODN integration into DSBs enhances sensitivity; quantitative correlation between the numbers of GUIDE-seq reads and mutation frequencies in living cells
Requires efficient cellular transfection of the dsODN tag, which can be challenging in sensitive cell types or in vivo settings HTGTS 10, 15, 16 Detects off-target nuclease-induced DSBs by observation of translocation junctions between two nuclease-induced DSBs Can be applied to discovering nuclease-induced off-targets when the nucleases are delivered in vivo Nuclease-induced translocations are rare; translocations occur more frequently with sites in the same chromosome or in close nuclear proximity BLESS/ BLISS 10, 17, 18 , End-seq 20 , and DSBCapture 19 Based on in situ ligation of adapters to transient nuclease-induced DSBs in fixed cells Does not require delivery and incorporation of exogenous DNA for detection Lack information about nuclease-induced DSBs that were previously repaired by the cell repair machinery Digenomeseq 10, 21, 22 In vitro method based on detection of Cas9-cleaved genomic DNA by wholegenome sequencing Does not require PCR; has also been tested with base editors Does not enrich for nuclease-cleaved sequences and requires a large number of sequencing reads (~400 million); high level of background; yields only one-half of the cleaved site; lacks information about how cellular factors affect nuclease off-target activity Site-seq 23 An in vitro method based on Cas9 cleavage of high-molecular-weight DNA, followed by enzymatic fragmentation, biotinylated adapter ligation, enrichment and sequencing Enriches for nuclease-cleaved fragments; reduces the number of sequencing reads required Reads contain only one-half of the cleaved sites; lacks information about how cellular factors affect nuclease off-target activity CIRCLE-seq 9 In vitro method in which genomic DNA is randomly fragmented, followed by circularization and generation of covalently closed dsDNA molecules. Circular dsDNAs are cleaved by Cas9 at on-and off-target sites, allowing the selective sequencing of nuclease-induced DSBs High enrichment, so fewer reads are required (3-5 million reads); reads contain both halves of the cleavage sites Lacks information about how cellular factors affect nuclease off-target activity; requires a large amount of gDNA whether off-target sites identified by these methods result in bona fide off-target mutagenesis in the actual cells or tissues modified by genome-editing nucleases.
Integration-defective lentiviral (IDLV) 11 capture and genome-wide unbiased identification of DSBs enabled by sequencing (GUIDE-seq) 12, 13 are cell-based, end-capture methods for defining sites of nuclease-induced DSBs by incorporation of exogenous DNA sequences, followed by tag-specific amplification. IDLV capture was the first method for unbiased identification of nuclease-induced DSBs 14 ; its sensitivity is limited to sites with mutagenesis frequencies of~5%. GUIDE-seq is based on the principle of efficient incorporation of a short, end-protected double-stranded DNA tag into the sites of nuclease-induced DSBs, tag-specific amplification and high-throughput sequencing; it has improved sensitivity compared with IDLV capture and can detect off-target sites that occur with frequencies as low as~0.1%.
High-throughput genome-wide translocation 15, 16 is a cell-based technique for off-target discovery that relies on the detection of translocations between two DSBs, a nuclease-induced 'bait' DSB and an off-target 'prey' DSB. Translocations occur more frequently with sites on the same chromosome or chromosomes that are in close nuclear proximity. Thus, translocation frequency is not predicted to correlate well with nuclease-induced mutation frequency.
BLESS (breaks labeling, enrichment on streptavidin and next-generation sequencing) 17 , BLISS (breaks labeling in situ and sequencing) 18 and DSBCapture 19 are in situ methods for detecting genome-wide nuclease-induced DSBs in fixed cells. BLESS, BLISS and DSBCapture detect nuclease activity by ligation of adapters to unrepaired DSBs in fixed cells and do not depend on (i) the delivery and incorporation of exogenous DNA or (ii) the endogenous cellular DNA damage repair machinery for detection of cuts in the DNA. End-seq 20 is a similar in situ method for detecting genome-wide nuclease activity that detects DSBs in cells embedded in agarose rather than fixed cells. One limitation of these in situ methods is that they capture only a snapshot of DSBs that exist at the moment in time in which the cells are fixed and are insensitive to previously repaired DSBs.
Digenome-seq 21, 22 is an in vitro and PCR-free method for detecting Cas9 cut sites in bulk gDNA by whole-genome sequencing (WGS). This method is performed by digesting gDNA with ribonucleoprotein (RNP) complex in vitro, followed by random DNA shearing, adapter ligation to all free ends (nuclease-and non-nuclease-induced) and WGS. gDNA fragments are sequenced to~30-50× coverage using~400 million paired-end reads, and then are mapped to a reference genome, where positions of uniformly mapping ends are computationally identified as sites of likely Cas9 DSBs. Owing to the high uniform background of random gDNA reads, it can be challenging to distinguish low-frequency nuclease-induced cleavage events from background.
SITE-seq 23 is another in vitro method for enrichment and sequencing of Cas9-cleaved gDNA, based on the isolation of high-molecular-weight gDNA to minimize the number of available DNA ends; cleavage with Cas9 RNP; biotinylated adapter ligation; enzymatic fragmentation; a second adapter ligation step to the enzymatically fragmented DNA ends; and enrichment. SITE-seq and Digenome-seq reads yield only one-half of the cleavage site, in contrast to CIRCLE-seq reads, which contain both halves.
Advantages
CIRCLE-seq has a number of advantages over other methods. As compared with Digenome-seq, CIRCLE-seq virtually eliminates the high background of random reads. Owing to high levels of enrichment for nuclease-cleaved gDNA fragments, fairly minimal amounts of sequencing reads are required to successfully perform the assay (~3-5 million).
CIRCLE-seq is more sensitive than cell-based methods for genome-wide off-target detection. For most targets, CIRCLE-seq can identify all off-target sites in human gDNA found by GUIDE-seq, one of the most sensitive cell-based methods. In addition, CIRCLE-seq also identified new bona fide offtarget sites that occur in human cells, demonstrating that it can detect novel sites that are below the limits of detection of GUIDE-seq 12 . A unique feature of the CIRCLE-seq method is that gDNA circles linearized by CRISPR-Cas nuclease cleavage contain both ends of the cleaved DNA molecule. Thus, CIRCLE-seq enables reference-genome-independent off-target discovery, an advantage in organisms lacking full genomic sequence or those with high genetic variability.
Because CIRCLE-seq is a cell-free technique that directly maps nuclease-induced DSBs, it does not rely on cellular DNA damage repair pathways for detection and is not influenced by the Cas9 delivery method.
Limitations CIRCLE-seq may detect some sites that cannot be confirmed in cells because (i) some sites that can be cleaved in purified gDNA in vitro may not be cleaved in cells because of limited chromatin accessibility or other cellular factors; (ii) some sites may fall below the limits of detection in current highthroughput sequencing technologies; and (iii) some sites may be cleaved in vitro under high enzyme concentration conditions that may not be achieavable in corresponding cell-based experiments. Conversely, typically all sites that are detected by cell-based approaches will be captured by in vitro techniques such as CIRCLE-seq.
Each CIRCLE-seq sample requires a relatively large amount of gDNA for circularization (~25 µg), which can be a limiting factor, depending on the availability of the cellular source of gDNA. This represents the yield of gDNA from~5 million diploid cells.
Choice of experimental method
The choice of method for determining genome-wide off-target activity of CRISPR-Cas nucleases depends on the primary experimental question at hand. In vitro methods such as CIRCLE-seq, Digenome-seq and SITE-seq are the most comprehensive, although activity in cells must be verified in subsequent sequencing experiments. End-capture methods, such as GUIDE-seq, directly and quantitatively measure off-target mutagenesis in cells but have limitations for consistent detection of sites with mutations with frequencies <0.1%. In situ ligation-based techniques detect unrepaired DSBs and may be useful for understanding the kinetics of on-target and off-target genome editing.
Experimental design
Overview of the workflow The CIRCLE-seq protocol can be divided into eight stages ( gDNA input CIRCLE-seq requires~25 µg of gDNA (input amount before shearing) per nuclease-treated or control sample. The expected yield of purified, circularized DNA is~1-2%. sgRNA sgRNA can be obtained by in vitro transcription from a plasmid template or, alternatively, by commercial synthesis. It is ideal to use the same source of sgRNA as that used in cell-based experiments.
Controls required
One negative control is required for each unique source of gDNA used in CIRCLE-seq experiments and should be accounted for when considering gDNA input requirements. The negative control is processed in exactly the same manner as other samples but with water substituted for CRISPR-Cas RNP at the nuclease cleavage step. This requires that a negative control sample be sequenced along with all nuclease-treated samples.
Reaction master mixes
Include a standard excess of 15-20% when making all library preparation reaction master mixes to account for losses while pipetting.
Genomic DNA shearing and gDNA circularization Purified gDNA is sheared to an average size of 300 bp. The fragmented DNA is ligated (by T4 DNA ligase) to a uracil-containing stem-loop adapter via a standard high-throughput sequencing library preparation method 24 . Adapter-ligated DNA molecules are selected over molecules that do not have adapters ligated to both ends (using lambda exonuclease and E. coli exonuclease I). Adapter-ligated DNA is then enzymatically treated (by USER enzyme and T4 PNK) to expose palindromic 4-nt (nucleotide) overhangs at both ends. DNA circularization (by T4 DNA ligase) is performed at a low DNA concentration (5 ng/µl), favoring intramolecular ligation, followed by selection of covalently closed circular DNA (using plasmid-safe ATP-dependent DNase). For any particular source of gDNA, circularized gDNA can be prepared in advance and stored long term at −20°C.
In vitro cleavage of circularized gDNA by RNP and NGS library preparation In vitro cleavage reaction of circularized gDNA is performed with SpCas9 RNP complexes. First, the capability of the specific RNP complex to cleave its target DNA should be tested on an amplicon containing the intended target sequence. Typical reaction conditions (1-h incubation and a relatively high 10:1 RNP/DNA molar ratio) are chosen to ensure near-complete cleavage, as we have previously observed that lowering the ratio of RNP/DNA reduces both fractions of amplicon cleavage and the number of CIRCLE-seq sites detected 9 . Next, RNP-digested products are ligated to adapters for sequencing.
Size selection
After adapter ligation, DNA size selection (250-850 bp) can be optionally performed, followed by PCR. Although not strictly required, DNA size selection avoids the presence of adapter dimers during PCR that might compete with the adapter-ligated DNA fragments for library enrichment. Elimination of adapter dimers before sequencing is recommended to increase library diversity and sequencing quality, and to prevent loss of time and material in the case of failure or poor results due to adapter dimers.
Sample barcodes
Dual-index barcodes (NEBNext Multiplex Oligos for Illumina) are used to distinguish individual CIRCLE-seq libraries and are added by PCR in
Step 74, allowing library multiplexing and increasing sample identification specificity. Ensure that combinations of dual-index barcodes are unique within sequencing runs.
Quantification and sequencing
Completed libraries are preferably quantified by droplet digital PCR 25 (a method that enables estimation of unwanted adapter dimer frequencies) and sequenced with 150-bp paired-end reads on an Illumina MiSeq instrument. Library quantification can also be performed using alternative methods such as standard qPCR 25 . Each pair of reads generated by Cas9 cleavage contains complete sequence information for a single on-or off-target site. CIRCLE-seq requires a modest 3-5 million sequencing reads per sample, making the technique accessible to most labs.
CIRCLE-seq data analysis
Our freely available, open-source CIRCLE-seq data analysis pipeline (https://github.com/tsailabSJ/ circleseq, https://doi.org/10.5281/zenodo.1284440) can be installed on most Mac or Linux-based operating systems. The pipeline takes as input FASTQ files and a user-generated manifest file in YAML format and produces output tables and visualization of sites of genome-wide activity of CRISPR-Cas nucleases in vitro.
Materials Biological materials
• U2OS cells (ATCC, cat. no. HTB-96) ! CAUTION Check cell lines regularly for mycoplasma contamination and authenticity.
• GM12878 cells (Coriell Institute, cat. no. GM12878) ! CAUTION Check cell lines regularly for mycoplasma contamination and authenticity.
Reagents sgRNA preparation • sgRNA in vitro transcription plasmid pCRL1 or equivalent (Addgene)
• Oligonucleotides for sgRNA construction (IDT, Tris-HCl 10 mM + 0.1% (vol/vol) Tween 20 solution can be stored at room temperature for several months.
U2OS culture medium
For culture of human U2OS cells, prepare Advanced DMEM medium supplemented with 1× GlutaMAX, 10% (vol/vol) FBS and 1× penicillin-streptomycin, and sterile-filter using a 500-ml filter unit. Store the medium at 4°C for up to 1 month.
GM12878 culture medium
For culture of human GM12878 cells, prepare RPMI 1640 medium supplemented with 10% (vol/vol) FBS and 1× penicillin-streptomycin, and sterile-filter using a 500-ml filter unit. Store the medium at 4°C for up to 1 month.
0.1× Elution buffer
Dilute elution buffer in UltraPure water to a 0.1× working solution, and store at room temperature for up to several months.
SOC medium
Reconstitute one capsule of SOB in 500 ml of water. Autoclave the mixture to sterilize. Allow the SOB to cool before adding kanamycin; then add glucose to a final concentration of 20 mM. SOC medium can be stored at room temperature for up to 3 months.
LB medium
Reconstitute LB medium (Luria broth base) at a concentration of 25 g per liter in deionized water and swirl to mix. Autoclave the mixture to sterilize. Allow the LB to cool before adding kanamycin to a final concentration of 50 μg/ml. LB medium can be stored at room temperature for up to 3 months.
LB agar plates (100-mm Petri dish, kanamycin) Reconstitute the LB agar at a concentration of 32 g per liter in deionized water and swirl to mix. Autoclave the mixture to sterilize. Allow the LB agar to cool to~65°C before adding kanamycin to a final concentration of 50 μg/ml. Pour 25 ml of LB agar per 100-mm dish. Place the lids on the plates and allow them to cool until solidified. Invert the plates and let them sit overnight. Agar plates can be stored in plastic bags at 4°C for up to 3 months.
1× TAE electrophoresis buffer Dilute 50× TAE electrophoresis buffer to 1× in distilled water, using 20 ml of 50× TAE electrophoresis buffer and 980 ml of distilled water. Typically, 1× TAE is made up right before use but can be stored at 25°C indefinitely. Wash the plate with 25 ml of PBS, add 5 ml of warmed trypsin-EDTA to a 150-mm plate and incubate at 37°C for 5 min. Add 20 ml of warmed advanced DMEM medium (prepared as described for U2OS cell culture medium in 'Reagent setup') to inactivate the trypsin, and transfer the cells to a 50-ml conical tube. Centrifuge at room temperature for 5 min at 300g and discard the supernatant. Resuspend the cells in 10 ml of PBS. Take a 10-µl aliquot of the cells resuspended in PBS, mix 1:1 with trypan blue and count with a hemocytometer. Prepare aliquots of 2 × 10 7 cells per tube, centrifuge at room temperature for 3 min at 5,000g and discard the supernatant. j PAUSE POINT Cell pellet(s) can be frozen at -20°C for several months. (B) GM12878 maintenance culture (i) Culture the cells in RPMI-1640 medium supplemented with 10% (vol/vol) FBS and 1× penicillin-streptomycin at 37°C and 5% CO 2 in T-75 flasks. (ii) As these cells grow in suspension, to passage, collect the medium containing the cells into 50-ml conical tubes, centrifuge at room temperature for 10 min at 300g and discard the supernatant. Resuspend the cells in fresh pre-warmed RPMI-1640 medium (prepared as described for GM12878 cell culture medium in the 'Reagent setup' section) by pipetting them up and down gently, and then reseed them into new T75 flasks, splitting in a 1:2-1:3 ratio. (iii) Harvest the cells by collecting the medium containing the cells into 50-ml conical tubes, centrifuge at room temperature for 10 min at 300g and discard the supernatant. Resuspend the cells in 10 ml of PBS and count with a hemocytometer. Prepare aliquots of 2 × 10 7 cells per tube, and spin down at 5,000g for 3 min at 25°C. Aspirate the PBS. with trypan blue and count with a hemocytometer. Prepare aliquots of 2 × 10 7 cells per tube, and spin down at 5,000g for 3 min at 25°C. j PAUSE POINT Cell pellets can be frozen at −20°C for several months.
Genomic DNA isolation • Timing 1 d
2 Perform gDNA isolation with a Gentra Puregene Tissue Kit, following the manufacturer's instructions. 3 Resuspend the cell pellet in 200 µl of PBS in a 15-ml conical tube, add 3 ml of cell lysis solution (supplied with the Gentra Puregene Tissue Kit) and 15 µl of proteinase K, mix by inverting 25 times and incubate at 55°C with shaking for 3 h or overnight for maximum yield. 4 Add 15 µl of RNase A solution and mix by inverting 25 times. Incubate at 37°C for 1 h. 5 Incubate for 1 min on ice and add 1 ml of protein precipitation solution (provided with the Gentra Puregene Tissue Kit). Vortex vigorously for 20 s at high speed. Centrifuge at room temperature for 10 min at 2,000g. The precipitated proteins should form a tight pellet. If the protein pellet is not tight, incubate on ice for 5 min and repeat the centrifugation. 6 Pipette 3 ml of isopropanol into a clean 15-ml conical tube and add the supernatant from the previous step by pipetting carefully. Mix by inverting 50 times. Centrifuge at room temperature for 3 min at 2,000g. Carefully discard the supernatant and drain the tube by inverting on a clean piece of absorbent paper, taking care that the DNA pellet remains in the tube. c CRITICAL STEP Make sure that the protein pellet is not dislodged from the original tube during removal of the supernatant, and discard the original tube with the protein pellet once the supernatant has been collected. 7 Add 3 ml of 70% (vol/vol) ethanol and invert several times to wash the DNA pellet. Centrifuge at room temperature for 1 min at 2,000g. Discard the supernatant. 8 Air-dryfor5-10 min. Add 400 µl of DNA hydration solution (supplied with the Gentra Puregene Tissue Kit), and mix well by pipetting up and down. Incubate at 65°C for 1 h to dissolve the DNA. Incubate at room temperature overnight. Briefly centrifuge at room temperature for 1 min at 2,000g and quantify gDNA by Qubit fluorometer, using the Qubit dsDNA BR Assay Kit and proper Qubit assay tubes. c CRITICAL STEP Do not overdry the pellet, as the DNA will be difficult to dissolve. j PAUSE POINT Isolated gDNA can be stored at −20°C for several months. (xvii) Incubate the in vitro transcription reaction in a thermocycler at 37°C for 16 h. Add 1 µl of DNase I (2 U/µl) and incubate at 37°C for 15 min. (xviii) Clean up the in vitro-transcribed product with the MEGAclear Transcription Clean-Up Kit, following the manufacturer's instruction. Elute sgRNA with 50 µl of pre-warmed (95°C) elution buffer. After the centrifugation step, collect the eluted product and reload into the column in order to perform a second elution step to increase the yield. Quantify the sgRNA by NanoDrop. Run 100 ng of each sgRNA on the QIAxcel instrument for sgRNA quality control, using the QIAxcel RNA QC Kit v2.0, QX RNA size marker (200-6,000 nt) and QX RNA alignment marker, following the manufacturer's instructions. j PAUSE POINT Prepare 5-µl aliquots and freeze at −80°C. sgRNA aliquots can be stored at −80°C for several months. Table 2) 0.5 0.1 µM oSQT1144 R (10 µM) ( 11 Perform the PCR using the following thermocycling conditions to amplify on-target locus. Optimize the conditions as required to obtain a single, sharp band when analyzed on a QIAxcel instrument or by standard gel electrophoresis.
Step , Springer Nature Limited.
29 End repair. Set up the end-repair master mix using components provided with the KAPA HTP Library Preparation (PCR-free) Kit: 47 Incubate in a thermocycler at 37°C for 1 h, and hold at 4°C. Table 2) 0.055 250 nM Probe oSQT1311 (100 µM) ( Table 2) 0.055 250 nM Primer oSQT1274 (100 µM) ( Table 2) 0.099 450 nM Primer oSQT1275 (100 µM) ( 
Troubleshooting
Troubleshooting advice can be found in Table 3 .
Timing
Step 1 
Anticipated results
Before proceeding with the full CIRCLE-seq protocol, it is important to first functionally test the ability of an RNP complex of interest to cleave a target site containing a DNA amplicon. It is expected that this cleavage reaction should proceed to near completion (Fig. 3a) . 
